Drugs / anti-SARS-Cov-2 vaccination
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05655351 | Dec 2022 → Jul 2024 | Coronaviridae infectious disease | Nîmes University Hospital | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anti-SARS-Cov-2 vaccination | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05655351 ↗ |
| Modality | Messenger RNA (mRNA) | “SARS-CoV-2 mRNA vaccines, known to cause the circulation of the vaccine antigen” PMID 39800264 ↗ Jan 2025 |